Renascience Inc.
Announcement of Clinical Trial Initiation in Saudi Arabia | July 2026
Lenascience Inc. has initiated Phase I clinical trials in collaboration with KAIMRC in Saudi Arabia, scheduled to be completed by the end of December 2026. The clinical trial evaluates the safety and tolerability of RS5614, with plans to proceed to Phase II trials thereafter.
Key Figures
- Start Date of Clinical Trial: 2026-07-21
- Scheduled Completion Date: 2026-12-31
- Clinical Trial Costs: Unknown
AI要約
Overview of the Clinical Trial
Lenascience Inc., in collaboration with KAIMRC in Saudi Arabia, has commenced Phase I clinical trials of RS5614. The trial evaluates safety and tolerability and is scheduled to be completed by the end of December 2026. The trial is conducted in Saudi Arabia and represents an important step toward future Phase II trials.
Future Outlook and Impact on Performance
Depending on the results of this clinical trial, development of anti-aging and longevity therapeutics is expected to progress, with potential future commercialization and revenue generation. However, at this stage, the direct impact on performance is expected to be minimal, and additional information will be disclosed as developments occur.
Lenascience Inc.
Company overview · Stock price · Financial data · All IR
